190 related articles for article (PubMed ID: 24866341)
1. Design and synthesis of quinazolinone tagged acridones as cytotoxic agents and their effects on EGFR tyrosine kinase.
Babu YR; Bhagavanraju M; Reddy GD; Peters GJ; Prasad VV
Arch Pharm (Weinheim); 2014 Sep; 347(9):624-34. PubMed ID: 24866341
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and molecular docking studies of 2-(furan-2-yl)quinazolin-4-one derivatives as potential antiproliferative agents.
Ahmed MF; Belal A
Arch Pharm (Weinheim); 2015 Jul; 348(7):487-97. PubMed ID: 25921702
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells.
Rajendra Prasad VV; Deepak Reddy G; Kathmann I; Amareswararao M; Peters GJ
Bioorg Chem; 2016 Feb; 64():51-8. PubMed ID: 26657603
[TBL] [Abstract][Full Text] [Related]
4. Studies for development of novel quinazolinones: new biomarker for EGFR.
Aggarwal S; Sinha D; Tiwari AK; Pooja P; Kaul A; Singh G; Mishra AK
Spectrochim Acta A Mol Biomol Spectrosc; 2015 May; 143():309-18. PubMed ID: 25766241
[TBL] [Abstract][Full Text] [Related]
5. Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies.
Murahari M; Prakash KV; Peters GJ; Mayur YC
Eur J Med Chem; 2017 Oct; 139():961-981. PubMed ID: 28886509
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of a novel series of 6,8-dibromo-4(3H)quinazolinone derivatives as anticancer agents.
Ahmed MF; Youns M
Arch Pharm (Weinheim); 2013 Aug; 346(8):610-7. PubMed ID: 23873839
[TBL] [Abstract][Full Text] [Related]
8. Molecular design, synthesis and biological research of novel pyridyl acridones as potent DNA-binding and apoptosis-inducing agents.
Zhang B; Chen K; Wang N; Gao C; Sun Q; Li L; Chen Y; Tan C; Liu H; Jiang Y
Eur J Med Chem; 2015 Mar; 93():214-26. PubMed ID: 25686590
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase.
Abouzid K; Shouman S
Bioorg Med Chem; 2008 Aug; 16(16):7543-51. PubMed ID: 18678492
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
[TBL] [Abstract][Full Text] [Related]
11. Structure-based drug design and biological evaluation of 2-acetamidobenzothiazole derivative as EGFR kinase inhibitor.
Gabr MT; El-Gohary NS; El-Bendary ER; El-Kerdawy MM
J Enzyme Inhib Med Chem; 2015 Feb; 30(1):160-5. PubMed ID: 24601650
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, molecular docking and antitumor activity of novel pyrrolizines with potential as EGFR-TK inhibitors.
Belal A
Bioorg Chem; 2015 Apr; 59():124-9. PubMed ID: 25748126
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, biological evaluation, molecular docking and QSAR studies of 2,4-dimethylacridones as anticancer agents.
Murahari M; Kharkar PS; Lonikar N; Mayur YC
Eur J Med Chem; 2017 Apr; 130():154-170. PubMed ID: 28246041
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antitumor activities of some new N1-(flavon-6-yl)amidrazone derivatives.
Habashneh AY; El-Abadelah MM; Zihlif MA; Imraish A; Taha MO
Arch Pharm (Weinheim); 2014 Jun; 347(6):415-22. PubMed ID: 24615985
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study.
El-Azab AS; Al-Omar MA; Abdel-Aziz AA; Abdel-Aziz NI; el-Sayed MA; Aleisa AM; Sayed-Ahmed MM; Abdel-Hamide SG
Eur J Med Chem; 2010 Sep; 45(9):4188-98. PubMed ID: 20599299
[TBL] [Abstract][Full Text] [Related]
16. Targeting tyrosine kinase: Development of acridone - pyrrole - oxindole hybrids against human breast cancer.
Kaur M; Singh P
Bioorg Med Chem Lett; 2019 Jan; 29(1):32-35. PubMed ID: 30446310
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors.
Wang J; Huang L; Chen X; Yuan Y; Sun J; Yang M
Chem Pharm Bull (Tokyo); 2022; 70(9):637-641. PubMed ID: 36047235
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies.
Gade DR; Makkapati A; Yarlagadda RB; Peters GJ; Sastry BS; Rajendra Prasad VVS
Comput Biol Chem; 2018 Jun; 74():63-75. PubMed ID: 29547875
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
Aziz MW; Kamal AM; Mohamed KO; Elgendy AA
Bioorg Med Chem Lett; 2021 Jun; 41():127987. PubMed ID: 33771586
[TBL] [Abstract][Full Text] [Related]
20. EGFR inhibition by pentacyclic triterpenes exhibit cell cycle and growth arrest in breast cancer cells.
Sathya S; Sudhagar S; Sarathkumar B; Lakshmi BS
Life Sci; 2014 Jan; 95(1):53-62. PubMed ID: 24333132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
